Review article: Maintenance treatment of Crohn's disease

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 17, Issue 2, 2003, Pages 31-37

  Biancone, L ^a   Tosti, C ^a   Fina, D ^a   Fantini, M ^a   De Nigris, F ^a   Geremia, A ^a   Pallone, F ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Fondazione Promoter   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANAMNESIS; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; ENDOSCOPY; HEADACHE; HISTOPATHOLOGY; HOST; HUMAN; IMMUNOCOMPETENT CELL; MAINTENANCE THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; SIDE EFFECT; SYMPTOM;

ADRENAL CORTEX HORMONES; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MESALAMINE; PHENYLHYDRAZINES; RECURRENCE; REMISSION INDUCTION; SULFASALAZINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037560089     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (62)

1. Fiocchi C. Inflammatory Bowel Disease. Etiology and Pathogenesis. Gastroenterology 1998; 115: 182-205.
2. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's Disease and ulcerative colitis: a study of 700 patients. Medicine 1976; 55: 401-7.
3. Pallone F, Borivant M, Stazi MA, et al. An analysis of clinical course of postoperative recurrence in Crohn's Disease of distal ileum. Dig Dis Sci 1992; 37: 215-9.
4. Elton E, Hanauer SB. Review article: The medical management of Crohn's Disease. Aliment Pharmacol Ther 1997; 10: 1-22.
5. Hanauer SB, Meyers S. Management of Crohn's Disease in adults. Am J Gastreonterol 1997; 92: 559-66.
6. Biancone L, Pallone F. Current treatment modalities in active Crohn's Disease. It J Gastroenterol Hepatol 1999; 31: 508-14.
7. Best WR, Becktel LM, Singleton JW, Kern F. Development of a Crohn's Disease Activity Index. Gastroenterology 1976; 70: 439-44.
8. Sachar DB, Andrews HA, Farmer RG, et al. Proposed classification of patient subgroups in Crohn's Disease. Working Team report. Gastroenterol Int 1992; 3: 141-54.
9. Bayless TM, Tokayer AZ, Polito LM, et al. Crohn's Disease: concordance for site and clinical type in affected family members - potential hereditary influences. Gastroenterology 1996; 111: 573-9.
10. Peeters M, Nevens H, Baert F, et al. Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastronterology 1996; 111: 597-603.
11. Polito JMII, Rees RC, Childs B, et al. Preliminary evidence of a genetic anticipation in Crohn's Disease. Lancet 1996; 347: 798-800.
12. Cottone M, Rosselli M, Orlando O, et al. Smoking habits and recurrence in Crohn's Disease. Gastroenterology 1994; 106: 643-8.
13. Arnott DR, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmaol Ther 2002; 16: 857-67.
14. Reinish W, Gasche G, Tillinger W, et al. Clinical relevance of serum interleukin-6 in Crohn's Disease: single point measurements, therapy monitoring and prediction of clinical relapse. Am J Gastroenterol 1999; 94: 2156-64.
15. Louis E, Belaiche J, Van Kemseke C, Schaaf N, Mahieu P, Mary JY. Soluble interleukin-2 receptor in Crohn's Disease. Assessment of disease activity and prediction of relapse. Dig Dis Sci 1995; 40: 1750-6.
16. Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn's Disease. Results of a prospective longitudinal study. J Clin Gastroenetrol 1988; 1084: 401-5.
17. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's Disease. Lancet 1993; 341: 1437-9.
18. Tibble JA, Sightorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
19. Biancone L, Fantini M, Tosti C, Bozzi R, Vavassori P, Pallone F. Fecal alpha-1-antitrypsin as a marker of clinical relapse in patients with Crohn's disease of the distal ileum. Eur J Gastroenterol Hepatol 2003; 15(3): 261-6.
20. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1 beta relapse of Crohn's disease. Lancet 1999; 353: 459-61.
21. Annovazzi A, Biancone L, Caviglia R, et al. 99mTc-Interleukin-2 and 99mTc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease. Eur J Nucl Med 2003; 30(3): 374-82.
22. Greenfield SM, Punchard NA, Teare JP, Thompson RPH. The mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 369-83.
23. Ewe K, Herfarth C, Malkhow H, Jesinsky HJ. Postoperative recurrence of Crohn's Disease in remission to radicality of operation and sulphasalazine prophylaxis: a multicenter trial. Digestion 1989; 42: 224-32.
24. Baron JH, Bennett PN, Lennard Jones JE, et al. Sulphasalazine in asymptomatic Crohn's disease: a multicenter trial. Gut 1977; 18: 69-72.
25. Steinhart HA, Hempill D, Greemberg R. Sulfasalazine and mesalazine for maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastreonterol 1994; 89: 216-24.
26. Nielsen OH. Sulfasalazine intolerance: a retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gstroenterol 1982; 17: 389-93.
27. Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron NO, Truelove S. Distribution and metabolism in healthy volunteers of disodium azadisalicylate: a possible new drug for ulcerative colitis. Gut 1982; 23: 1081-7.
28. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's Disease: a multicenter placebo-controlled-study. The Group d'Etudes Therapeutiques des Affections Inflammatories Digestives (GETAID). Gastroenterology 1993; 104: 435-9.
29. International Mesalazine Study Group. Coated oral 5-amino-salicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther 1990; 4: 55-64.
30. Prantera C, Pallone F, Brunerri G, et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's Disease. Gastroenterology 1992; 103: 363-8.
31. Sutherland LR. Prevention of relapse of Crohn's Disease. Inflamm Bowel Dis 2000; 6(4): 321-8.
32. Summers RW, Switz DM, Sessions JT. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1984; 86: 249-66.
33. Malkow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-66.
34. Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990; 4: 407-14.
35. Greenberg GR, Feagan BG, Martin F and the Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn's Disease. N Engl J Med 1994; 331: 836-41.
36. Lofboerg R. Critical review: new steroids for inflammatory bowel disease. Inflamm Bowel Dis (CCFA J) 1995; 1: 135-61.
37. Rutgeerts P, Lofboerg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's Disease. N Engl J Med 1994; 331: 842-5.
38. Green JR, Lobo AJ, Giaffer M, et al. Maintenance of Crohn's Disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules. Aliment Pharmacol Ther 2001; 15(9): 1331-41.
39. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 years review. Gut 2002; 50(4): 485-9.
40. Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 2000; 14(12): 1561-5.
41. Willoughby JMT, Kumar PJ, Beckett J, Dawson AM. Controlled trial of azathioprine in Crohn's Disease. Lancet 1971; 2: 994-7.
42. Present DH, Korelitz BJ, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopruine. A long term randomized double blind study. N Engl J Med 1980; 302: 981-7.
43. Lewis JD, Schwartz JS, Linchtenstein GR. Azathioprine for maintenance of remission in Crohn's disease, benefits outweigh the risk of lymphoma. Gastroenterology 2000; 118(6): 1018-24.
44. Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5- aminosalicylate theraphy. Eur J Gastroenterol Hepatol 2001; 13(11): 1297-301.
45. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2000; 16(7): 1225-32.
46. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Hepatol 2000; 12(11): 1227-33.
47. Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 2000; 14(12): 1561-5.
48. Miller LC, Cohen SE, Orencole SF. Interleukin-1 is structurally related to dihydrofolate reductase, effects of methotrexate on IL-1. Lymphokine Res 1988; 7: 272A.
49. Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993; 38: 1851-6.
50. Feagan BG, Rochon J, Fedorak RN. Methotrexate for treatment of Crohn's Disease. N Engl J Med 1995; 332: 292-7.
51. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's Disease. North American Crohn's Study Group Investigator. N Engl J Med 1999; 342(22): 1627-32.
52. Fraser AG, Morton D, McGovern D, Travis S, Jewell DP. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16(4): 693-7.
53. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's Disease: long-term efficacy and toxicity. Am J Gastroenterol 2000; 95(7): 1730-4.
54. van Dullemen HM, deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109(1): 129-35.
55. Targan SR, Hanauer SB, vanDeventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337(15): 1029-35.
56. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001; 120(6): 1330-8.
57. d'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histologic healing with Infliximab anti-tumor necrosis factor antibodies in Crohn's Disease: a European Multicenter trial. Gastroenterology 1999; 116(5): 1029-34.
58. Mascheretti S, Hampe J, Croucher PJ, et al. Response to Infliximab treatment in Crohn's Disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002; 12(7): 509-12.
59. Vermiere S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's Disease. Gastroenterology 2002; 123(1): 106-11.
60. Rutgeerts P, dHaens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117(4): 761-9.
61. Rutgeerts P. Review article: efficacy of infliximab in Crohn's disease: induction and maintenance of remission. Aliment Pharmcol Ther 1999; 13(Suppl. 4): 9-15.
62. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT randomised trial. Lancet 2002; 359(9317): 1541-9.